Radioactive imaging test for brain inflammation in Alzheimer's
Part of Brain & nervous system clinical trials.
This trial tests a radioactive imaging agent that targets a protein in the brain linked to inflammation, to see if it can help track Alzheimer's disease. It may help doctors better understand your condition and guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your legal guardian must agree to join the study and sign a consent form.
- You must be between 18 and 75 years old, of any gender.
- You must have a diagnosis of Alzheimer's disease confirmed by a positive amyloid PET scan.
- You must have already had a Tau PET scan.
- You cannot have a known allergy to TSPO-related drugs or have taken anti-inflammatory drugs in the last 14 days.
- You cannot have other serious brain diseases, mental health conditions, or metal implants that prevent MRI scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special imaging agent called [18F]NIDF to take pictures of tau protein clumps in the brain, which are linked to Alzheimer's and other memory or movement disorders. It may help doctors see these changes more clearly.
This study uses a special PET brain scan to look at two types of brain immune cells in people with Alzheimer’s. It may help researchers better understand Alzheimer’s and how these cells change over time.
This study uses a special PET scan to look for inflammation in the brains of people with Alzheimer's or related dementias. It may help researchers understand how inflammation affects memory and thinking problems.
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
This study tests a PET scan “tracer” medicine called [18F]MK-6240 to see how tau protein changes show up in the brain. It may help researchers measure disease-related brain changes in people with normal thinking or mild dementia.
This study uses a special PET scan to take pictures of abnormal tau protein in the brain. It aims to see if the scan results match what is found in brain tissue after death, which could help improve diagnosis of Alzheimer's and related conditions.
Hear when a new Alzheimer's Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.